Cirrhosis News and Research RSS Feed - Cirrhosis News and Research

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease. [More]
Experts urge baby boomers to get screened for HCV

Experts urge baby boomers to get screened for HCV

If you're a baby boomer, you may not know that odds are high that you're carrying the hepatitis C virus, putting yourself at risk for illness that can range from minor to life threatening. [More]
FDA designates Synageva's sebelipase alfa as Breakthrough Therapy for early onset LAL Deficiency

FDA designates Synageva's sebelipase alfa as Breakthrough Therapy for early onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease. [More]
Researchers link coffee consumption with reduced risk of primary sclerosing cholangitis

Researchers link coffee consumption with reduced risk of primary sclerosing cholangitis

Research presented today at Digestive Disease Week explores new discoveries in liver disease research, with findings about the impact of coffee on autoimmune disease and palliative care for cirrhotic patients. [More]
AGA researchers to present exciting data on GI disorders at DDW 2013

AGA researchers to present exciting data on GI disorders at DDW 2013

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2013, the largest and most prestigious gastroenterology meeting, from May 18 to 21, 2013, at the Orange County Convention Center in Orlando, FL. [More]
FDA approves Arbor Pharmaceuticals' NDA for Nymalize oral solution

FDA approves Arbor Pharmaceuticals' NDA for Nymalize oral solution

Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved its New Drug Application for Nymalize (nimodipine) oral solution. [More]
Understanding different forms of hepatitis

Understanding different forms of hepatitis

It's Hepatitis Awareness Month. Understanding the different forms of hepatitis, who is at risk and how it can be prevented and treated can be confusing. [More]
Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today reported 12-month results from an ongoing extension study with sebelipase alfa in adults with late onset Lysosomal Acid Lipase Deficiency. [More]
HCV screening of prison inmate drug users: an interview with Dr. Arthur Kim, Massachusetts General Hospital and Harvard Medical School

HCV screening of prison inmate drug users: an interview with Dr. Arthur Kim, Massachusetts General Hospital and Harvard Medical School

Prisoners overall have a very high rate of past or present injection drug use, which is a major risk factor for HCV infection due to repeated exposures to needles. [More]

Study: Biologic response modifying drugs can cause acute liver injury

A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection. [More]
Baby boomers need to get tested for hepatitis C

Baby boomers need to get tested for hepatitis C

If you were born during 1945-1965, talk to your doctor about getting tested for hepatitis C. Baby boomers are five times more likely than other adults to be infected. In fact, 75 percent of adults with hepatitis C were born during these years. [More]
UK’s health performance: an interview with Prof. Murray, University of Washington

UK’s health performance: an interview with Prof. Murray, University of Washington

Rates of premature mortality in the UK have been falling steadily, but the pace of decline is not as fast as in many other high-income countries, such as Australia. In that sense, the UK lags behind. [More]
GS-9620 therapy suppresses hepatitis B virus infection

GS-9620 therapy suppresses hepatitis B virus infection

A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells. [More]

New rationale for treating patients with cirrhosis and portal hypertension

New data from clinical studies presented for the first time at the International Liver Congress- 2013 provide new rationale for an old and established treatment option for portal hypertension. [More]
Study demonstrates accuracy of non-invasive test for NASH diagnosis

Study demonstrates accuracy of non-invasive test for NASH diagnosis

A Chinese study presented at the International Liver CongressTM 2013 has demonstrated the accuracy of a non-invasive test for non-alcoholic steatohepatitis (NASH) diagnosis. [More]
Calcipotriol drug offers a potential treatment option for fibrotic diseases

Calcipotriol drug offers a potential treatment option for fibrotic diseases

Liver fibrosis results from an excessive accumulation of tough, fibrous scar tissue and occurs in most types of chronic liver diseases. In industrialized countries, the main causes of liver injury leading to fibrosis include chronic hepatitis virus infection, excess alcohol consumption and, increasingly, nonalcoholic steatohepatitis (NASH). [More]

Research shows probiotics reduce the development of hepatic encephalopathy

Probiotics could emerge as a treatment plan to manage hepatic encephalopathy (HE) therapy after a new study announced at the International Liver Congress- 2013 found they significantly reduced development of the notoriously difficult-to-treat disease. [More]
Urine tests could improve diagnosis of liver cancer

Urine tests could improve diagnosis of liver cancer

New data from two clinical trials presented today at the International Liver Congress- 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests. [More]
Research reveals deadly impact of alcohol and body weight on liver disease

Research reveals deadly impact of alcohol and body weight on liver disease

Research announced today at the International Liver CongressTM 2013 has revealed the deadly impact that alcohol and body weight have on liver disease. [More]